ANEBULO PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $198.53 thousand for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $198.53K, a 64.82% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $237.64K, a 17.17% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $255.27K, a 68.34% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-12-31 was $564.33K, a 157.38% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.45M, a 90.65% increase from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $758.88K, a 14.22% decline from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $884.72K, a 84.06% increase from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $480.66K, a 140.39% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $198.53K 10-Q · filed 2026-02-12 | $436.17K derived: sum of 2 quarters · filed 2026-02-12 | ||
| 2025-09-30 | $237.64K 10-Q · filed 2026-02-12 | |||
| 2025-06-30 | $1.45M 10-K · filed 2025-09-29 | |||
| 2025-03-31 | $255.27K 10-Q · filed 2025-05-13 | $819.60K derived: sum of 2 quarters · filed 2026-02-12 | $1.11M derived: sum of 3 quarters · filed 2026-02-12 | |
| 2024-12-31 | $564.33K 10-Q · filed 2026-02-12 | $851.25K derived: sum of 2 quarters · filed 2026-02-12 | ||
| 2024-09-30 | $286.92K 10-Q · filed 2026-02-12 | |||
| 2024-06-30 | $758.88K 10-K · filed 2025-09-29 | |||
| 2024-03-31 | $151.64K 10-Q · filed 2025-05-13 | $370.90K derived: sum of 2 quarters · filed 2025-05-13 | $581.70K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $219.26K 10-Q · filed 2025-05-13 | $430.06K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-09-30 | $210.80K 10-Q · filed 2025-05-13 | |||
| 2023-06-30 | $884.72K 10-K · filed 2024-09-25 | |||
| 2023-03-31 | $223.64K 10-Q · filed 2024-05-15 | $449.26K derived: sum of 2 quarters · filed 2024-05-15 | $661.16K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $225.62K 10-Q · filed 2024-05-15 | $437.52K derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2022-09-30 | $211.90K 10-Q · filed 2024-05-15 | |||
| 2022-06-30 | $480.66K 10-K · filed 2023-09-22 | |||
| 2022-03-31 | $125.25K 10-Q · filed 2023-05-11 | $219.54K derived: sum of 2 quarters · filed 2023-05-11 | $253.71K derived: sum of 3 quarters · filed 2023-05-11 | $369.15K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $94.28K 10-Q · filed 2023-05-11 | $128.46K derived: sum of 2 quarters · filed 2023-05-11 | $243.89K derived: sum of 3 quarters · filed 2023-05-11 | $291.30K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-09-30 | $34.17K 10-Q · filed 2023-05-11 | $149.61K derived: sum of 2 quarters · filed 2023-05-11 | $197.02K derived: sum of 3 quarters · filed 2023-05-11 | $217.71K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-06-30 | $115.44K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | $162.84K derived: sum of 2 quarters · filed 2022-09-09 | $183.54K derived: sum of 3 quarters · filed 2022-09-09 | $199.95K 10-K · filed 2022-09-09 |
| 2021-03-31 | $47.41K 10-Q · filed 2022-05-11 | $68.10K derived: sum of 2 quarters · filed 2022-05-11 | $84.51K 10-Q · filed 2021-06-21 | |
| 2020-12-31 | $20.69K 10-Q · filed 2022-05-11 | $37.10K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-09-30 | $16.41K 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |